Decellularized bone extracellular matrix embedded with PLGA-linezolid microparticles for infected bone regeneration.
Ebrahimi F., Jalali H., Kalantari N., Ghanian MH., Hosseini S.
Animal Study, published in Biomed Eng Online (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomed Eng Online (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41310716
- PMCID
- PMC12659149
- DOI
- 10.1186/s12938-025-01478-2
Abstract (original English)
Background Dual-functional antibacterial and osteogenic substitutes are advanced tools for treating bone infections while facilitating bone regeneration. These systems incorporate drug delivery mechanisms that allow for the local release of antibiotics and increased treatment efficacy. Decellularized bone extracellular matrix (dECM) offers key advantages for bone xenografts and local drug delivery due to its biocompatibility and low immunogenicity. This study developed a novel scaffold by loading linezolid-poly (lactic-co-glycolic acid) (PLGA-Lin) microparticles onto dECM derived from bovine tibia. The antibacterial activity, cytocompatibility, and osteoconductive properties of the resulting Lin-PLGA/dECM scaffold were assessed in vitro. Results The results revealed that the dECM had a porous structure and the Lin-PLGA microparticles infiltrated the scaffold. None of the dECM, PLGA/dECM, or Lin-PLGA/dECM scaffolds had toxic effects on adipose tissue-derived mesenchymal stem cells (ADSCs), while the inhibitory effect of Lin-PLGA/dECM on the Staphylococcus aureus strain was significant. All scaffolds-dECM, PLGA/dECM, and Lin-PLGA/dECM-promoted the bone differentiation of ADSCs, as confirmed by alkaline phosphatase (ALP) and calcium content assays, as well as by the expression of the Runt-related transcription factor 2 (Runx2), osteopontin, osteocalcin, and collagen Iα genes. Conc
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.